RESEARCH PAPER
Identity and organizational models of rare disease patient organizations: findings from a qualitative study
More details
Hide details
1
Faculty of Management, Warsaw University, Polska
Med Og Nauk Zdr. 2026;32(3):237-244
KEYWORDS
TOPICS
ABSTRACT
Introduction and objective:
Rare disease patient organizations (RDPOs) contribute to improving access to
healthcare, medicines, psychosocial support, and social services for people living with rare diseases (RD). Limited evidence exists on how they develop their organizational identity and how this influences their patterns of collective action. The study examines how RDPOs organize activities and how disease affiliation shapes organizational identity, culture, and strategy.
Material and methods:
A qualitative study design was adopted. Data were collected over a 3-year period through
non-participant observation, 20 interviews with Polish RDPOs, and documents review followed by reflexive thematic analysis. Methodological triangulation was applied to enhance study
credibility.
Results:
RDPOs comprise small and homogeneous communities of patients and caregivers, facilitating alignment between activities and community needs. Organizational identity is grounded in affiliation with a specific RD, distinguishing them from other NGOs, shaping their functional model. RD affiliation provides basis for collaboration at home and promotes participation in international networks. Advances in medical knowledge accompany increasing organizational specialization, reflected in the growing number of organizations representing single RDs. This pattern has been observed for over 20 years in Poland and the EU
Conclusions:
RDPOs constitute a key healthcare component, supporting advocacy, public education, R&D, and collaboration with policy stakeholders. Disease-specific identity and community homogeneity facilitate relationship-based networks at both national and international levels. These findings suggest that collaboration, rather than competition, characterizes their organizational development and shapes policies strengthening patient participation in health systems.
PEER REVIEW INFORMATION
Article has been screened for originality
REFERENCES (25)
1.
The Lancet Global Health. The landscape for rare diseases in 2024. Lancet Glob Health. 2024;12(3):341. doi:10.1016/S2214-109X(24)00056-1.
3.
Braga LAM, Conte Filho CG, Mota FB. Future of genetic therapies for rare genetic diseases: what to expect for the next 15 years? Ther Adv Rare Dis. 2022;3:26330040221100840. doi:10.1177/26330040221100840.
5.
Domike R, Raju GK, Sullivan J, Kennedy A. Expediting treatments in the 21st century: Orphan Drugs and accelerated approvals. Orphanet Journal of Rare Diseases. 2024;19(1). doi:10.1186/s13023-024-03398-1.
6.
Dumbuya JS, Zeng C, Deng L, et al. The impact of rare diseases on the quality of life in paediatric patients: Current status. Frontiers in Public Health. 2025;13. doi:10.3389/fpubh.2025.1531583.
7.
Claessens Z, Vanneste A, Van Isterdael C et al. Criteria to evaluate unmet health-related needs of persons living with rare diseases and their caregivers: Rapid Literature Review and stakeholder consultations. Orphanet Journal of Rare Diseases. 2025;20(1). doi:10.1186/s13023-025-03838-6.
8.
Al-Attar M, Butterworth S, McKay L. A quantitative and qualitative analysis of patient group narratives suggests common biopsychosocial red flags of undiagnosed rare disease. Orphanet J Rare Dis. 2024;19:172. doi:10.1186/s13023-024-03143-8 20:321.
9.
Klein Haneveld MJ, Vyshka K, Gaasterland CMW, et al. ‘Mind the Gap’-A Survey on Care Gaps and Priorities for the Transition to Adult Healthcare According to Caregivers of Young People with Rare Conditions Associated with Intellectual Disability. J Intellect Disabil Res. 2025. doi:10.1111/jir.13229.
11.
Bowles J, Clifford D, Mohan J. The place of charity in a public health service: Inequality and persistence in charitable support for NHS trusts in England. Social Science & Medicine. 2023;322.
12.
Mavris M, Le C. Involvement of patient organisations in research and development of orphan drugs for rare diseases in Europe. Syndromol, 2020;3(5):237–243.
13.
Stasiewicz-Swinney A. Pacjent w systemie ochrony zdrowia. In: Haczyński J, Skrzypczak Z, editors. Ochrona zdrowia i gospodarka. Przegląd współczesnych problemów systemu opieki zdrowotnej. Warszawa: Sekcja Wydawnicza Wydziału Zarządzania Uniwersytetu Warszawskiego; 2022. p. 95–120.
14.
Briscoe F, Gupta A. Social Activism in and Around Organisations. The Academy of Management Annals. 2016;10(1):671–727.
16.
Kociatkiewicz J, Kostera M. Zaangażowane badania jakościowe. Problemy Zarządzania. 2013;1(1):9–17.
17.
Bryda G. CAQDAS a badania jakościowe w praktyce. Przegląd Socjologii Jakościowej. 2014;10(2):12–38.
18.
Poteete A, Janssen MA, Ostrom E. Working Together: Collective Action, the Commons, and Multiple Methods in Practice. Princetown: Prince town University Press, 2010.
19.
Belančić A, Gkrinia EM, Likić R, Vitezić D. Navigating challenges and opportunities in orphan medicines: A spotlight commentary on rare diseases. Br J Clin Pharmacol. 2025;91(4):1084–1087. doi:10.1002/bcp.70013.
20.
Gonzato O, Gronchi A. The evolving role of patients advocates in rare cancers: Opportunities and challenges. Expert Review of Pharmacoe-conomics & Outcomes Research. 2019;19(1):1–3.
https://doi.org/10.1080/147371....
21.
Gentilini A, Neez E, Wong-Rieger D. Rare Disease Policy in High-Income Countries: An Overview of Achievements, Challenges, and Solutions. Value in Health. 2025;28(5):680–685.
https://doi.org/10.1016/j.jval....
23.
Sommer N, Klug J. Knowledge Helps: Handling Rare Diseases in Regular Schools. Contin Educ. 2024;5(1):22–30. doi:10.5334/cie.99.
24.
Zamora-Bonilla J. Public choice versus social choice as theories of collective action. In: Kincaid H, Van Bouwel J, editors. Oxford Handbook of Philosophy of Political Science. Oxford: Oxford University Press;2023. p. 141–188.
25.
Władysiuk M, Libura M, Rolska-Wójcik P, Plisko P. Rola organizacji pacjentów w systemach opieki zdrowotnej w Polsce i na świecie. Warszawa: Raport Pacjenci Pro; 2021.